Gaps in treatment amongst metastatic castration resistant prostate cancer (mCRPC) patients taking abiraterone acetate or enzalutamide.

被引：0
|
作者：
Behl, Ajay
Ellis, Lorie
Pilon, Dominic
Xiao, Yongling
Lefebvre, Patrick
Dawson, Nancy Ann
机构：
[1] Janssen Sci Affairs LLC, Horsham, PA USA
[2] 1000 Gauchetiere Ouest, Montreal, PQ, Canada
[3] Grp Anal Ltee, Montreal, PQ, Canada
[4] Lombardi Comprehens Canc Ctr, Washington, DC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 02期
关键词：
D O I：
10.1200/jco.2016.34.2_suppl.334
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
334
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Abiraterone Acetate In Metastatic Castration-Resistant Prostate Cancer
    Yang, Lily P. H.
    DRUGS, 2011, 71 (15) : 2067 - 2077
  • [32] Real-world treatment with abiraterone acetate in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)
    Boegemann, Martin
    Hatzinger, Martin
    Hercher, Dirko
    Matus, Geoffrey
    Everaert, Els Grieta
    Dopchie, Catherine
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [33] Sequencing of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer (mCRPC)
    Schnadig, Ian D.
    Bhor, Menaka
    Vogelzang, Nicholas J.
    Hennessy, Daniel
    Nicacio, Leonardo V.
    Berry, William R.
    Hutson, Thomas E.
    Fleming, Mark T.
    Cowey, C. Lance
    Saravanan, Shanmugapriya
    Dhanda, Rahul
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [34] Efficacy of Enzalutamide Following Abiraterone Acetate in Chemotherapy- naive Metastatic Castration-resistant Prostate Cancer Patients
    Azad, Arun A.
    Eigl, Bernhard J.
    Murray, R. Nevin
    Kollmannsberger, Christian
    Chi, Kim N.
    EUROPEAN UROLOGY, 2015, 67 (01) : 23 - 29
  • [35] Medication Adherence, Treatment Patterns, and Dose Reduction in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone Acetate or Enzalutamide
    Behl, Ajay S.
    Ellis, Lorie A.
    Pilon, Dominic
    Xiao, Yongling
    Lefebvre, Patrick
    AMERICAN HEALTH AND DRUG BENEFITS, 2017, 10 (06): : 296 - 302
  • [36] Effect of IL-6 and related mediators on resistance to abiraterone acetate (abi) and enzalutamide (enza) in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Adashek, Jacob J.
    Won, Haejung
    Moreira, Dayson
    Duttagupta, Priyanka
    Twardowski, Przemyslaw
    Jones, Jeremy
    Kortylewski, Marcin
    Pal, Sumanta K.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [37] A multicenter population-based experience with abiraterone acetate (AA) in patients with metastatic castration resistant prostate cancer (mCRPC)
    Clayton, Ravinder
    Heng, Daniel Yick Chin
    Wu, Jackson S. Y.
    Zielinski, Rob
    North, Scott A.
    Emmenegger, Urban
    Hotte, Sebastien J.
    Al-Shamsi, Humaid Obaid
    Chen, Leo
    Eigl, Bernhard J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [38] Concomitant antihypertensive medication and outcome of patients with metastatic castration-resistant prostate cancer receiving enzalutamide or abiraterone acetate
    Fiala, Ondrej
    Hosek, Petr
    Korunkova, Hana
    Hora, Milan
    Kolar, Jiri
    Sorejs, Ondrej
    Topolcan, Ondrej
    Filipovsky, Jan
    Liska, Vaclav
    Santoni, Matteo
    Buti, Sebastiano
    Finek, Jindrich
    CANCER MEDICINE, 2024, 13 (01):
  • [39] Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC)
    Pal, Sumanta Kumar
    Patel, Jaymala
    He, Miaoling
    Foulk, Brad
    Kraft, Katherine
    Smirnov, Denis A.
    Twardowski, Przemyslaw
    Kortylewski, Marcin
    Bhargava, Vipul
    Jones, Jeremy O.
    CANCER, 2018, 124 (06) : 1216 - 1224
  • [40] ABIRATERONE AND ENZALUTAMIDE FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) POST CHEMOTHERAPY: AN INDIRECT COMPARISON AND BUDGET IMPACT ANALYSIS
    Li, T.
    Thompson, M.
    Todd, M.
    Yu, M.
    Kheoh, T.
    Saadi, R.
    VALUE IN HEALTH, 2013, 16 (07) : A394 - A394
12345